购物车
- 全部删除
- 您的购物车当前为空
BC-DXI-843 是特异性 AIMP2-DX2抑制剂(IC50:0.92 μM),比作用于 AIMP2 (IC50 >100 μM) 选择性高 100 倍以上。它具有用于 AIMP2-DX2 肺癌的研究潜力。
为众多的药物研发团队赋能,
让新药发现更简单!
BC-DXI-843 是特异性 AIMP2-DX2抑制剂(IC50:0.92 μM),比作用于 AIMP2 (IC50 >100 μM) 选择性高 100 倍以上。它具有用于 AIMP2-DX2 肺癌的研究潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 217 | 现货 | |
5 mg | ¥ 539 | 现货 | |
10 mg | ¥ 912 | 现货 | |
25 mg | ¥ 1,690 | 现货 | |
50 mg | ¥ 2,500 | 现货 | |
100 mg | ¥ 3,590 | 现货 | |
200 mg | ¥ 4,970 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 750 | 现货 |
产品描述 | BC-DXI-843 is inhibitor of AIMP2-DX2, and is potential for development of novel therapeutics targeting AIMP2-DX2 in lung cancer. |
靶点活性 | AIMP2-DX2:0.92 μM (IC50), AIMP2:IC50 >100 μM |
体外活性 | Optimization of hit BC-DXI-04 (IC50 = 40.1 μM) provided new potent sulfonamide based AIMP2-DX2 inhibitors.?Among these, BC-DXI-843 showed improved inhibition against AIMP2-DX2 (IC50 = 0.92 μM) with more than 100-fold selectivity over AIMP2 in a luciferase assay.?Several binding assays indicated that this compound effectively induces cancer cell apoptosis by specifically interrupting the interaction between DX2 and HSP70, which leads to the degradation of DX2 via Siah1-mediated ubiquitination. |
体内活性 | BC-DXI-843 demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg, suggesting it as a promising lead for development of novel therapeutics targeting AIMP2-DX2 in lung cancer. |
分子量 | 546.66 |
分子式 | C28H26N4O4S2 |
CAS No. | 2421117-98-6 |
Smiles | COc1ccc(cc1)-c1csc(NC(=O)[C@H](Cc2c[nH]c3ccccc23)NS(=O)(=O)c2ccc(C)cc2)n1 |
密度 | 1.381 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 245 mg/mL (448.18 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容